source
- Genmab faces steep revenue cliff as Darzalex patents expire, eyes pivotal Epkinly readoutGenmab relies heavily on Darzalex, a cancer drug co‑developed with Johnson & Johnson, which currently provides about 90% of the company’s sales. U.S. patents for Darzalex are set to expire in 2029,…
- Researchers develop tumor "avatar" model that predicts immunotherapy response with 93% accuracyResearchers at Elephas Biosciences, in collaboration with academic centers, created an ex vivo tumor "avatar" from patient biopsies to test how tumors respond to immunotherapy. They exposed 124 tu…